［1］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
［2］Wang Jinpeng，Tang Yanyan.The role of exosomal non-coding RNAs in cancer metastasis［J］.Oncotarget，2018，9(15)：12487-12502.
［3］Sun W，Zhang K，Zhang X，et al.Identification of differentially expressed genes in human lung squamous cell carcinoma using suppression subtractive hybridization［J］.Cancer Lett，2004，212：83-93.
［4］Yoshimura S，Gerondopoulos A，Linford A，et al.Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors［J］.J Cell Biol，2010，191：367-381.
［5］Ling B.Suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D［J］.Lung Cancer，2013，79：104-110.
［6］Vyas S，Matic，Uchima L，et al.Family-wide analysis of poly(ADP-ribose) polymerase activity［J］.Nat Commun，2014，5：4426.
［7］Gupte R，Liu ZY,Kreus WL.PARPs and ADP-ribosylation：Recent advances linking molecular functions to biological outcomes［J］.Genes & Development，2017，31(2)：101-126.
［8］Ali SO，Khan FA.Understanding specific functions of PARP-2：New lessons for cancer therapy［J］.American Journal of Cancer Research，2016，6(9)：1842-1863.
［9］Brandon Carney，Susanne Kossatz.Target engagement imaging of PARP inhibitors in small-cell lung cancer［J］.Nature Communications，2018，9：176.
［10］Stewart CA，Tong P.Dynamic variations in epithelial-to-mesenchymal transition(EMT)，ATM，and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer［J］.Oncotarget，2017，8(17)：28575-28587.
［11］Paola Castri，Yang-ja Lee，Todd Ponzio，et al.Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-κB-dependent signaling［J］.HHS Author Manuscripts，2014，1843(3)：640-651.
［12］Ling B.A research of the suppression of non-small cell lung cancer proliferation and tumorigenicity by DENND2D［D］.Beijing：Peking Union Medical College，2012.［凌兵.DENND2D抑制非小细胞肺癌增殖能力和致瘤性的研究［D］.北京：北京协和医学院，2012.］
［13］Li LC，Jayaram S.Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells［J］.HHS Author Manuscripts，2011，205(4)：362，e12-e25.
［14］Andrea Turner，Liang Cheng.MADD Knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells［J］.PLoS One，2013，8(2)：e56817.
［15］Mitsuro K，Dai S，Shuji N.et al.Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer［J］.Gastric Cancer，2015，18(2)：288-296.
［16］Hibino S，Kanda M，Oya H，et al.Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus［J］.Oncol Rep，2014，31(2)：693-700.
［17］Kanda M，Nomoto S.Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma［J］.Int J Oncol，2014，44(1)：44-52.
［18］Mitsuro Kanda，Kenta Murotani，Hiroyuki Sugimoto，et al.An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma［J］.Oncotarget，2017，8(41)：71070-71079.
［19］Petersen S，Aninat-Meyer M，Schluns K，et al.Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung［J］.Br J Cancer，2000，82：65-73.
［20］Zhang T.Downregulation of miR-522 suppresses proliferation and metastasis of non-small cell lung cancer cells by directly targeting DENN/MADD domain containing 2D［J］.Sci Rep，2016，6：19346.
［21］Sujata Sakha，Tomoki Muramatsu.Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma［J］.Scientific Reports，2016，6：38750.
［22］Maria Vila-Casadesús，Elena Vila-Navarro.Deciphering microRNA targets in pancreatic cancer using miRComb R package［J］.Oncotarget，2018，9(5)：6499-6517.
［23］Daniel Morgensztern，Meghan J，Campo，et al.Molecularly targeted therapies in non-small lung cancer annual update 2014［J］.HHS Author Manuscripts，2015，10(101)：S1-63.
［24］Mitsuro Kanda，Hiroyuki Sugimoto.Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma［J］.World J Gastroenterol，2015，21(37)：10584-10597.
［25］Huang CC，Tu SH.Concurrent gene signatures for han Chinese breast cancers［J］.PLoS One，2013，8(10)：e76421.
［26］Kristensen LS，Asmar F，Dimopoulos K，et al.Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma［J］.Oncotarget，2014，5(20)：9798-9810.
［27］Kang N，Choi SY.Silencing of miR-137 by aberrant promoter hypermethylation in surgically resected lung cancer［J］.Lung Cancer，2015，89(2)：99-103.
［28］Hwang JA，Hong SH.HOXA9 inhibits migration of lung cancer cells and its hypermethylation is associated with recurrence in non-small cell lung cancer［J］.Mol Carcinog，2015，54（Suppl 1）：E72-80.
［29］Gregory A Masters，Sarah Temin.Systemic therapy for stage Ⅳ non-small cell lung cancer：American society of clinical oncology clinical practice guideline update［J］.Journal of Clinical Oncology，2015，33(30)：3488-3515.
［30］Sean Blandin Knight，Crosbie，Haval Balata，et al.Progress and prospects of early detection in lung cancer［J］.Open Biology，2017，7(9)：170070.
［31］Mitsuro Kanda，Yasuhiro Kodera.Recent advances in the molecular diagnostics of gastric cancer［J］.World J Gastroenterol，2015，21(34)：9838-9852.
［32］Jill E Larsen，John D，Minna，et al.Molecular biology of lung cancer：Clinical implications［J］.Hhs Author Manuscripts，2011，32(4)：703-740.
［33］Ling B，Feng L，Cheng SJ，et al.Effect of DENND2D on cisplatin cytotoxicity in non-small cell lung cancer cell line H1299 by regulating PARP［J］.Carcinogenesis，Teratogenesis & Mutagenesis，2013，25(2)：87-90.［凌兵，冯林，程书钧，等.DENND2D通过调控PARP1对非小细胞肺癌细胞系H1299中顺铂细胞毒性的影响［J］.癌变 畸变 突变，2013，25(2)：87-90.］
［34］Luo X，Kraus WL.On PAR with PARP：Cellular stress signaling through poly(ADP-ribose) and PARP-1［J］.Genes & Development，2012，26(5)：417-432.
［35］Maliuchenko NV，Kulaeva OI，Kotova E，et al.Molecular mechanisms of regulaion of transcription by PARP1［J］.Mol Biol (Mosk)，2015，49(1)：99-113.
［36］Schiewer MJ，Knudsen KE.Transcriptional roles of PARP1 in cancer［J］.Mol Cancer Res，2014，12(8)：1069-1080.